NASDAQ:BBIO - BridgeBio Pharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $31.83
  • Forecasted Upside: 174.43 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$11.60
▲ +0.72 (6.62%)

This chart shows the closing price for BBIO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BridgeBio Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BBIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BBIO

Analyst Price Target is $31.83
▲ +174.43% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for BridgeBio Pharma in the last 3 months. The average price target is $31.83, with a high forecast of $75.00 and a low forecast of $18.00. The average price target represents a 174.43% upside from the last price of $11.60.

This chart shows the closing price for BBIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 contributing investment analysts is to buy stock in BridgeBio Pharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/18/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/19/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/17/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/15/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/13/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/14/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/13/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/12/2022

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/26/2022SVB LeerinkBoost Price TargetOutperform$27.00 ➝ $30.00Low
6/15/2022The Goldman Sachs GroupBoost Price TargetBuy ➝ Buy$19.00 ➝ $21.00Low
5/24/2022The Goldman Sachs GroupLower Price TargetBuy$24.00 ➝ $19.00High
3/16/2022HC WainwrightLower Price TargetBuy$24.00 ➝ $22.00High
3/11/2022JPMorgan Chase & Co.Lower Price TargetOverweight$21.00 ➝ $18.00High
3/4/2022SVB LeerinkBoost Price TargetOutperform$24.00 ➝ $25.00Medium
1/31/2022HC WainwrightReiterated RatingBuy$24.00Low
12/28/2021HC WainwrightLower Price TargetBuy$88.00 ➝ $24.00Medium
12/27/2021SVB LeerinkLower Price TargetOutperform$66.00 ➝ $24.00N/A
12/27/2021MizuhoLower Price TargetBuy$86.00 ➝ $25.00N/A
11/19/2021SVB LeerinkLower Price TargetOutperform$68.00 ➝ $66.00High
11/3/2021MizuhoReiterated RatingBuyMedium
10/25/2021HC WainwrightReiterated RatingBuyHigh
10/13/2021MizuhoInitiated CoverageBuy$86.00Medium
10/4/2021SVB LeerinkBoost Price TargetOutperform$66.00 ➝ $68.00Medium
9/10/2021Bank of AmericaUpgradeNeutral ➝ Buy$75.00Low
8/6/2021SVB LeerinkLower Price TargetOutperform$71.00 ➝ $66.00Medium
7/16/2021SVB LeerinkReiterated RatingOutperformLow
5/20/2021UBS GroupInitiated CoverageBuy$80.00Low
5/7/2021The Goldman Sachs GroupLower Price TargetBuy$92.00 ➝ $80.00High
4/11/2021SVB LeerinkReiterated RatingBuyLow
3/23/2021Jefferies Financial GroupReiterated RatingBuy$79.00Medium
3/23/2021SVB LeerinkBoost Price TargetOutperform$67.00 ➝ $75.00High
3/22/2021The Goldman Sachs GroupBoost Price TargetPositive ➝ Buy$83.00 ➝ $91.00High
3/20/2021MizuhoInitiated CoverageBuy$86.00High
3/4/2021MizuhoBoost Price TargetBuy$56.00 ➝ $86.00Low
2/22/2021JPMorgan Chase & Co.Initiated CoverageOverweightMedium
2/9/2021The Goldman Sachs GroupReiterated RatingBuy$83.00 ➝ $83.00Low
1/11/2021HC WainwrightBoost Price TargetBuy$64.00 ➝ $87.00High
12/14/2020BTIG ResearchBoost Price TargetBuy$49.00 ➝ $91.00High
12/10/2020HC WainwrightBoost Price TargetBuy$53.00 ➝ $64.00Low
12/4/2020SVB LeerinkBoost Price TargetOutperform$39.00 ➝ $44.00Medium
12/2/2020MizuhoBoost Price TargetBuy$51.00 ➝ $56.00High
11/5/2020Piper SandlerBoost Price TargetOverweight$50.00 ➝ $60.00Low
10/12/2020HC WainwrightBoost Price TargetBuy$50.00 ➝ $53.00Low
10/6/2020BMO Capital MarketsBoost Price TargetOutperform$44.00 ➝ $49.00High
9/30/2020The Goldman Sachs GroupBoost Price Target$43.00 ➝ $52.00High
8/12/2020HC WainwrightReiterated RatingBuy$50.00High
6/25/2020Bank of AmericaInitiated CoverageNeutral$38.00High
6/11/2020HC WainwrightReiterated RatingBuy$50.00Medium
5/19/2020BTIG ResearchInitiated CoverageBuy$49.00Low
5/14/2020SVB LeerinkLower Price TargetOutperform$41.00 ➝ $39.00High
4/13/2020HC WainwrightInitiated CoverageBuy$50.00High
3/3/2020JPMorgan Chase & Co.Boost Price TargetOverweight$38.00 ➝ $43.00Low
2/18/2020MizuhoInitiated CoverageBuy$51.00High
1/7/2020Raymond JamesBoost Price Target$36.00 ➝ $40.00Low
12/3/2019UBS GroupInitiated CoverageReduceHigh
10/18/2019Piper Jaffray CompaniesDropped CoverageBuy$50.00N/A
7/26/2019Raymond JamesInitiated CoverageOutperform ➝ Outperform$36.00High
7/22/2019SVB LeerinkInitiated CoverageOutperform ➝ Outperform$34.00High
7/22/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$38.00High
7/22/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$38.00High
7/22/2019Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$50.00High
7/22/2019The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$42.00High
7/22/2019BMO Capital MarketsInitiated CoverageOutperform ➝ Outperform$49.00High
(Data available from 8/12/2017 forward)

News Sentiment Rating

0.82 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 10 very positive mentions
  • 12 positive mentions
  • 7 negative mentions
  • 6 very negative mentions
1/14/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/13/2022
  • 5 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
3/15/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/14/2022
  • 4 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
5/14/2022
  • 0 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
6/13/2022
  • 7 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
7/13/2022
  • 9 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/12/2022

Current Sentiment

  • 9 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
BridgeBio Pharma logo
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
Read More

Today's Range

Now: $11.60
Low: $10.92
High: $11.84

50 Day Range

MA: $9.08
Low: $5.95
High: $11.99

52 Week Range

Now: $11.60
Low: $4.98
High: $18.13

Volume

1,933,722 shs

Average Volume

2,583,736 shs

Market Capitalization

$1.72 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.72

Frequently Asked Questions

What sell-side analysts currently cover shares of BridgeBio Pharma?

The following Wall Street sell-side analysts have issued research reports on BridgeBio Pharma in the last year: Bank of America Co., HC Wainwright, JPMorgan Chase & Co., Mizuho, SVB Leerink LLC, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for BBIO.

What is the current price target for BridgeBio Pharma?

6 Wall Street analysts have set twelve-month price targets for BridgeBio Pharma in the last year. Their average twelve-month price target is $31.83, suggesting a possible upside of 174.4%. Bank of America Co. has the highest price target set, predicting BBIO will reach $75.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $18.00 for BridgeBio Pharma in the next year.
View the latest price targets for BBIO.

What is the current consensus analyst rating for BridgeBio Pharma?

BridgeBio Pharma currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BBIO will outperform the market and that investors should add to their positions of BridgeBio Pharma.
View the latest ratings for BBIO.

What other companies compete with BridgeBio Pharma?

How do I contact BridgeBio Pharma's investor relations team?

BridgeBio Pharma's physical mailing address is 421 Kipling Street, Palo Alto CA, 94301. The company's listed phone number is (650) 391-9740. The official website for BridgeBio Pharma is bridgebio.com. Learn More about contacing BridgeBio Pharma investor relations.